Xalatan and Acute lymphocytic leukemia (all) - a phase IV clinical study of FDA data

Summary:

Acute lymphocytic leukemia (all) is reported only by a few people who take Xalatan.

The phase IV clinical study analyzes which people take Xalatan and have Acute lymphocytic leukemia (all). It is created by eHealthMe based on reports of 24,358 people who have side effects while taking Xalatan from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 28, 2023

24,358 people reported to have side effects when taking Xalatan.
Among them, 3 people (0.01%) have Acute lymphocytic leukemia (all).

What is Xalatan?

Xalatan has active ingredients of latanoprost. It is often used in glaucoma. eHealthMe is studying from 24,707 Xalatan users for its effectiveness, alternative drugs and more.

What is Acute lymphocytic leukemia (all)?

Acute lymphocytic leukemia (all) (cancer of the white blood cells characterized by excess lymphoblasts) is found to be associated with 1,003 drugs and 820 conditions by eHealthMe.

Number of Xalatan and Acute lymphocytic leukemia (all) reports submitted per year:

Could Xalatan cause Acute lymphocytic leukemia (all)?

Gender of people who have Acute lymphocytic leukemia (all) when taking Xalatan *:

female: 100 %
male: 0.0 %

Age of people who have Acute lymphocytic leukemia (all) when taking Xalatan *:

Common drugs people take besides Xalatan *:

Common side effects people have besides Acute lymphocytic leukemia (all) *:

Sepsis (a severe blood infection that can lead to organ failure and death): 2 people, 66.67%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 66.67%
Skin Discoloration: 1 person, 33.33%
Second Primary Malignancy (after getting cure a cancer, a new cancer development): 1 person, 33.33%
Rashes (redness): 1 person, 33.33%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 1 person, 33.33%
Muscle Spasms (muscle contraction): 1 person, 33.33%
Leukocytosis (increased white blood cells): 1 person, 33.33%
Fatigue (feeling of tiredness): 1 person, 33.33%

Common conditions people have *:

Diarrhea: 2 people, 66.67%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 2 people, 66.67%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 1 person, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Xalatan and have Acute lymphocytic leukemia (all)?

Check whether Acute lymphocytic leukemia (all) is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Acute lymphocytic leukemia (all) and when was it recovered:

Acute lymphocytic leukemia (all) in Xalatan

Expand to all the drugs that have ingredients of latanoprost:

Acute lymphocytic leukemia (all) and drugs with ingredients of latanoprost

Alternative drugs to, pros and cons of Xalatan:

Xalatan (24,707 reports)

Common Xalatan side effects:

Browse all side effects of Xalatan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Acute lymphocytic leukemia (all) treatments and more:

Acute lymphocytic leukemia (all) (37,157 reports)

COVID vaccines that are related to Acute lymphocytic leukemia (all):

Common drugs associated with Acute lymphocytic leukemia (all):

How the study uses the data?

The study uses data from the FDA. It is based on latanoprost (the active ingredients of Xalatan) and Xalatan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.